.tb-container[data-toolset-blocks-container="8c13577c35fd68d7b70a2a5270dfdf0d"] { border-radius: 10px;padding: 25px;box-shadow: 5px 5px 10px 0 rgba( 0, 0, 0, 0.5 ); } .tb-container[data-toolset-blocks-container="93f4094e2a5fc591c3cbd3f80a56f302"] { border-radius: 10px;padding: 25px;box-shadow: 5px 5px 10px 1px rgba( 0, 0, 0, 0.5 ); } .tb-button[data-toolset-blocks-button="905492d670a3f94a0bd953a7b3a4cad7"] { text-align: center; } .tb-button[data-toolset-blocks-button="905492d670a3f94a0bd953a7b3a4cad7"] .tb-button__link { background-color: rgba( 151, 91, 229, 1 );color: rgba( 255, 255, 255, 1 );box-shadow: 5px 5px 10px -5px rgba( 0, 0, 0, 0.5 ); } .tb-button[data-toolset-blocks-button="905492d670a3f94a0bd953a7b3a4cad7"] .tb-button__link:visited { color: rgba( 255, 255, 255, 1 ); } .tb-button[data-toolset-blocks-button="905492d670a3f94a0bd953a7b3a4cad7"] .tb-button__content { text-shadow: 5px 5px 10px rgba( 0, 0, 0, 0.5 );color: rgba( 255, 255, 255, 1 ); } .tb-button[data-toolset-blocks-button="905492d670a3f94a0bd953a7b3a4cad7"] .tb-button__icon { font-family: dashicons;margin-right: 10px; } .tb-button[data-toolset-blocks-button="905492d670a3f94a0bd953a7b3a4cad7"] .tb-button__icon::before { content: '\f103'; } .tb-grid[data-toolset-blocks-grid="ef19397a81dd17f19e5fc8b2cbc64a03"] { grid-template-columns: minmax(0, 0.3333fr) minmax(0, 0.3333fr) minmax(0, 0.3333fr);grid-auto-flow: row } .tb-grid[data-toolset-blocks-grid="ef19397a81dd17f19e5fc8b2cbc64a03"] > .tb-grid-column:nth-of-type(3n + 1) { grid-column: 1 } .tb-grid[data-toolset-blocks-grid="ef19397a81dd17f19e5fc8b2cbc64a03"] > .tb-grid-column:nth-of-type(3n + 2) { grid-column: 2 } .tb-grid[data-toolset-blocks-grid="ef19397a81dd17f19e5fc8b2cbc64a03"] > .tb-grid-column:nth-of-type(3n + 3) { grid-column: 3 } .tb-grid-column[data-toolset-blocks-grid-column="3034fbe886c11054e95b46b09d3e4112"] { display: flex; } .tb-fields-and-text[data-toolset-blocks-fields-and-text="d8ee833869d806ba93519c93a0c99d68"] { border-top: 1px dotted rgba( 0, 0, 0, 1 );border-right: 0px dashed rgba( 0, 0, 0, 1 );border-bottom: 0px dashed rgba( 0, 0, 0, 1 );border-left: 0px dashed rgba( 0, 0, 0, 1 ); } .tb-grid[data-toolset-blocks-grid="3d9c399fe625e1b972f817a0680229f6"] { grid-template-columns: minmax(0, 0.5fr) minmax(0, 0.5fr);grid-auto-flow: row } .tb-grid[data-toolset-blocks-grid="3d9c399fe625e1b972f817a0680229f6"] > .tb-grid-column:nth-of-type(2n + 1) { grid-column: 1 } .tb-grid[data-toolset-blocks-grid="3d9c399fe625e1b972f817a0680229f6"] > .tb-grid-column:nth-of-type(2n + 2) { grid-column: 2 } .tb-button[data-toolset-blocks-button="24f0f0d165901ec9701a2e67ad2f63d4"] { text-align: center; } .tb-button[data-toolset-blocks-button="24f0f0d165901ec9701a2e67ad2f63d4"] .tb-button__link { background-color: rgba( 151, 91, 229, 1 );color: rgba( 255, 255, 255, 1 );box-shadow: 5px 5px 10px 0 rgba( 0, 0, 0, 0.5 ); } .tb-button[data-toolset-blocks-button="24f0f0d165901ec9701a2e67ad2f63d4"] .tb-button__link:visited { color: rgba( 255, 255, 255, 1 ); } .tb-button[data-toolset-blocks-button="24f0f0d165901ec9701a2e67ad2f63d4"] .tb-button__content { color: rgba( 255, 255, 255, 1 ); } .tb-button[data-toolset-blocks-button="24f0f0d165901ec9701a2e67ad2f63d4"] .tb-button__icon { font-family: dashicons; } .tb-grid-column[data-toolset-blocks-grid-column="e863d66eac949908a5c6c8d2fd31320c"] { display: flex; } .tb-button[data-toolset-blocks-button="f987862329ab3042d8c291515c549fdd"] { text-align: center; } .tb-button[data-toolset-blocks-button="f987862329ab3042d8c291515c549fdd"] .tb-button__link { background-color: rgba( 151, 91, 229, 1 );color: rgba( 255, 255, 255, 1 );box-shadow: 5px 5px 10px 0 rgba( 0, 0, 0, 0.5 ); } .tb-button[data-toolset-blocks-button="f987862329ab3042d8c291515c549fdd"] .tb-button__link:visited { color: rgba( 255, 255, 255, 1 ); } .tb-button[data-toolset-blocks-button="f987862329ab3042d8c291515c549fdd"] .tb-button__content { color: rgba( 255, 255, 255, 1 ); } .tb-button[data-toolset-blocks-button="f987862329ab3042d8c291515c549fdd"] .tb-button__icon { font-family: dashicons; } @media only screen and (max-width: 781px) { .tb-grid[data-toolset-blocks-grid="ef19397a81dd17f19e5fc8b2cbc64a03"] { grid-template-columns: minmax(0, 0.3333fr) minmax(0, 0.3333fr) minmax(0, 0.3333fr);grid-auto-flow: row } .tb-grid[data-toolset-blocks-grid="ef19397a81dd17f19e5fc8b2cbc64a03"] > .tb-grid-column:nth-of-type(3n + 1) { grid-column: 1 } .tb-grid[data-toolset-blocks-grid="ef19397a81dd17f19e5fc8b2cbc64a03"] > .tb-grid-column:nth-of-type(3n + 2) { grid-column: 2 } .tb-grid[data-toolset-blocks-grid="ef19397a81dd17f19e5fc8b2cbc64a03"] > .tb-grid-column:nth-of-type(3n + 3) { grid-column: 3 } .tb-grid-column[data-toolset-blocks-grid-column="3034fbe886c11054e95b46b09d3e4112"] { display: flex; } .tb-grid[data-toolset-blocks-grid="3d9c399fe625e1b972f817a0680229f6"] { grid-template-columns: minmax(0, 0.5fr) minmax(0, 0.5fr);grid-auto-flow: row } .tb-grid[data-toolset-blocks-grid="3d9c399fe625e1b972f817a0680229f6"] > .tb-grid-column:nth-of-type(2n + 1) { grid-column: 1 } .tb-grid[data-toolset-blocks-grid="3d9c399fe625e1b972f817a0680229f6"] > .tb-grid-column:nth-of-type(2n + 2) { grid-column: 2 } .tb-grid-column[data-toolset-blocks-grid-column="e863d66eac949908a5c6c8d2fd31320c"] { display: flex; }  } @media only screen and (max-width: 599px) { .tb-grid[data-toolset-blocks-grid="ef19397a81dd17f19e5fc8b2cbc64a03"] { grid-template-columns: minmax(0, 1fr);grid-auto-flow: row } .tb-grid[data-toolset-blocks-grid="ef19397a81dd17f19e5fc8b2cbc64a03"]  > .tb-grid-column:nth-of-type(1n+1) { grid-column: 1 } .tb-grid-column[data-toolset-blocks-grid-column="3034fbe886c11054e95b46b09d3e4112"] { display: flex; } .tb-grid[data-toolset-blocks-grid="3d9c399fe625e1b972f817a0680229f6"] { grid-template-columns: minmax(0, 1fr);grid-auto-flow: row } .tb-grid[data-toolset-blocks-grid="3d9c399fe625e1b972f817a0680229f6"]  > .tb-grid-column:nth-of-type(1n+1) { grid-column: 1 } .tb-grid-column[data-toolset-blocks-grid-column="e863d66eac949908a5c6c8d2fd31320c"] { display: flex; }  } 
Báo cáo thường niên năm 2019 của Aptose Biosciences Inc.
Aptose Biosciences is a science-driven biotechnology company advancing first-in-class agents to treat life-threatening cancers, such as acute myeloid leukemia (AML), high-risk myelodysplastic syndromes (MDS) and other hematologic malignancies. Based on insights into the genetic and epigenetic profiles of certain cancers and patient populations, Aptose is building a pipeline of novel oncology therapies directed at dysregulated processes and signaling pathways. Aptose is developing targeted medicines for precision treatment of these diseases, based on a patient’s specific gene expression signature. In the treatment of cancer, this strategy is intended to optimize efficacy and quality of life by minimizing the cytotoxic side effects associated with conventional therapies.
Báo cáo thường niên của Liminal BioSciences Inc. năm 2019